OBJECTIVE: To investigate the effect of a matrix metalloproteinase (MMP) inhibitor, BB-94, on the viability, invasion, and metastases of pancreatic cancer. SUMMARY BACKGROUND DATA: Inhibitors of MMPs, enzymes that degrade extracellular matrix, have been tested as single chemotherapeutic agents for pancreatic cancer. METHODS: Capan1 and AsPC1 cell lines were studied. BB-94 cytotoxicity was evaluated by cell proliferation assays. Production of MMP2 and MMP9 in conditioned media was demonstrated by gelatin zymography. The in vitro effect of BB-94 on cell invasion was assayed using invasion chambers. Hepatic metastases from pancreatic cancer were induced by intrasplenic injections of Capan1 or AsPC1 cells in nude mice. The in vivo effect of BB-94 on liver metastases was evaluated by comparing animals receiving BB-94 treatment with controls receiving vehicle alone. Variables measured included death rate and tumor burden (liver-to-body weight ratio). RESULTS: BB-94 was not cytotoxic between 3 and 3,000 ng/mL. Zymography demonstrated production of MMP2 and MMP9 by both cell lines, with complete inhibition of these enzymes by BB-94 at 48 ng/mL. Invasion chamber assays showed that BB-94 (48-400 ng/mL) impeded cell invasion in vitro compared with untreated controls. In vivo, BB-94 prevented death or reduced the death rate from hepatic metastases in animals injected with Capan1 or AsPC1 cells. BB-94 treatment resulted in significant reductions in hepatic tumor burden compared with untreated controls. CONCLUSIONS: Inhibition of MMP reduces both growth of pancreatic cancer metastases and the death rate. These actions do not reflect cytotoxicity but rather result from impaired cancer cell attachment, migration, and organ invasion. MMP inhibitors may provide an additive effect to cytotoxic agents in multidimensional treatment regimens for pancreatic cancer.
OBJECTIVE: To investigate the effect of a matrix metalloproteinase (MMP) inhibitor, BB-94, on the viability, invasion, and metastases of pancreatic cancer. SUMMARY BACKGROUND DATA: Inhibitors of MMPs, enzymes that degrade extracellular matrix, have been tested as single chemotherapeutic agents for pancreatic cancer. METHODS: Capan1 and AsPC1 cell lines were studied. BB-94cytotoxicity was evaluated by cell proliferation assays. Production of MMP2 and MMP9 in conditioned media was demonstrated by gelatin zymography. The in vitro effect of BB-94 on cell invasion was assayed using invasion chambers. Hepatic metastases from pancreatic cancer were induced by intrasplenic injections of Capan1 or AsPC1 cells in nude mice. The in vivo effect of BB-94 on liver metastases was evaluated by comparing animals receiving BB-94 treatment with controls receiving vehicle alone. Variables measured included death rate and tumor burden (liver-to-body weight ratio). RESULTS:BB-94 was not cytotoxic between 3 and 3,000 ng/mL. Zymography demonstrated production of MMP2 and MMP9 by both cell lines, with complete inhibition of these enzymes by BB-94 at 48 ng/mL. Invasion chamber assays showed that BB-94 (48-400 ng/mL) impeded cell invasion in vitro compared with untreated controls. In vivo, BB-94 prevented death or reduced the death rate from hepatic metastases in animals injected with Capan1 or AsPC1 cells. BB-94 treatment resulted in significant reductions in hepatic tumor burden compared with untreated controls. CONCLUSIONS: Inhibition of MMP reduces both growth of pancreatic cancer metastases and the death rate. These actions do not reflect cytotoxicity but rather result from impaired cancer cell attachment, migration, and organ invasion. MMP inhibitors may provide an additive effect to cytotoxic agents in multidimensional treatment regimens for pancreatic cancer.
Authors: P Basset; J P Bellocq; C Wolf; I Stoll; P Hutin; J M Limacher; O L Podhajcer; M P Chenard; M C Rio; P Chambon Journal: Nature Date: 1990 Dec 20-27 Impact factor: 49.962
Authors: D Muller; R Breathnach; A Engelmann; R Millon; G Bronner; H Flesch; P Dumont; M Eber; J Abecassis Journal: Int J Cancer Date: 1991-06-19 Impact factor: 7.396
Authors: C Charpin; J C Lissitzky; J Jacquemier; M N Lavaut; F Kopp; N Pourreau-Schneider; P M Martin; M Toga Journal: Hum Pathol Date: 1986-04 Impact factor: 3.466
Authors: N Chandrasekar; S Jasti; W K Alfred-Yung; F Ali-Osman; D H Dinh; W C Olivero; M Gujrati; A P Kyritsis; G L Nicolson; J S Rao; S Mohanam Journal: Clin Exp Metastasis Date: 2000 Impact factor: 5.150
Authors: Hideaki Ijichi; Anna Chytil; Agnieszka E Gorska; Mary E Aakre; Brian Bierie; Motohisa Tada; Dai Mohri; Koji Miyabayashi; Yoshinari Asaoka; Shin Maeda; Tsuneo Ikenoue; Keisuke Tateishi; Christopher V E Wright; Kazuhiko Koike; Masao Omata; Harold L Moses Journal: J Clin Invest Date: 2011-09-19 Impact factor: 14.808
Authors: Beatrice E Kern; James H Balcom; Bozena A Antoniu; Andrew L Warshaw; Carlos Fernández-del Castillo Journal: J Gastrointest Surg Date: 2003-12 Impact factor: 3.452